Project Grant R21CA305319
Award Date
7/18/25
Completion Date
6/30/27
Dollars Obligated
$415K
Federal Agency
National Cancer Institute
Federal Grant Program
93.395
Assistance Type
Project Grant
Place of Performance
Massachusetts, USA
Similar Awards
This $1,008,000 Cooperative Agreement award was provided by the National Science Foundation (NSF) under the Technology, Innovation, and Partnerships (CFDA 47.084) program. The project aims to develop a high-throughput platform for screening millions of T-cell receptors (TCRs) against a large set of clinically relevant cancer antigens, in order to identify and validate promising TCRs for cancer-specific cell killing. The goal is to discover and validate multiple anti-cancer TCRs that could...
This $195,766 federal Project Grant, awarded on December 19, 2024 by the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research), supports research at Yale University to develop a mechano-transduction platform for enhancing chimeric antigen receptor (CAR) T-cell therapies for cancer immunotherapy. The key goals are to: 1) measure forces along immune receptors like the T-cell receptor and CAR using force sensors, and 2) engineer force transduction modules that can induce expression of...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports the development of a CD4 TCR-engineered T cell immunotherapy for the treatment of triple-negative breast cancer (TNBC). The award of $1,001,029.00 will fund the generation of a GMP-grade master cell bank and viral particles for the IMT-422 (CD4 TCR-STEM T cells) product, as well as the determination of its pharmacokinetics, biodistribution, and toxicity. This work aims to accelerate the...
This federal Project Grant award from the National Cancer Institute's Cancer Research Manpower program (CFDA 93.398) provides $132,462 to the Fred Hutchinson Cancer Center in Seattle, WA to support research aimed at improving engineered T cell receptor T cell (TCR-T) therapy for solid tumors. The key objectives are to: 1) Determine why TCR-T cells form a different reservoir of stem-like progenitor cells in tumor-draining lymph nodes compared to endogenous tumor-specific T cells, and 2)...
This federal Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $604,627 to the Trustees of Dartmouth College to conduct research aimed at deconvoluting the heterogeneity of chimeric antigen receptor (CAR) T cells in order to engineer durable antitumor immunity. The research project, which runs from January 1, 2025 to December 31, 2029, will use dynamic lineage recording to understand how individual CAR T cell subsets behave in vivo and...
This Project Grant award from the National Cancer Institute (NCI), under the Cancer Research Manpower (CFDA 93.398) program, provides $176,040 to The General Hospital Corporation (Massachusetts General Hospital) from July 1, 2025 to June 30, 2027. The project aims to develop new strategies to engineer CAR-T cell therapies that can overcome the cancer cell glycocalyx barrier for improved immunotherapy, particularly for solid tumors like breast cancer and glioblastoma. Key objectives include...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $249,645 to Boston Children's Hospital to develop advanced genetic engineering techniques to study the role of tumor-specific B cells in cancer progression. The researchers aim to genetically modify B cells to target the HER2 tumor antigen, with the goal of using these engineered B cells as an adoptive immunotherapy to trigger both humoral and cellular anti-tumor immune responses. The...
This $693,880 Project Grant award from the National Cancer Institute's Cancer Treatment Research program (CFDA 93.395) supports the development of a novel cancer immunotherapy approach using engineered CD4+ T cells. The goal is to create CD4+ T cells that can target the tumor microenvironment and overcome resistance to current immune checkpoint inhibitor therapies. Key elements include: Identifying key molecules and immune cell targets of the engineered CD4+ T cells in preclinical cancer...
This federal Project Grant award from the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower) provides $163,967 to President and Fellows of Harvard College (Harvard Medical School) to conduct research on defining the functional and spatial properties of tumor-specific, tumor-infiltrating CD8 T cells. The key objectives are to: Generate patient-derived xenograft (PDX) mouse models of melanoma to test the required diversity of T cell receptors (TCRs) from tumor-infiltrating T...
This Project Grant award from the National Cancer Institute's Cancer Detection and Diagnosis Research program (CFDA 93.394) provides $650,450 to the University of Southern California to develop a novel cancer immunotherapy using genetically engineered CD4+ T cells targeting the CT83 tumor antigen. The research aims to determine the mechanisms by which these engineered T cells eliminate lung cancer cells, produce GMP-grade master cell banks and viral particles, and develop a scalable...